| 20520641 |
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib
Menzel, H,
Sigl, M,
Rummelt, C,
Duyster, J,
von Bubnoff, N,
Peschel, C
|
Leukemia |
2010 |
| 28077790 |
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
Levis, M,
Nguyen, B,
Williams, AB,
Small, D,
Brown, P,
Li, L,
Young, DJ,
Ma, H
|
Oncotarget |
2017 |
| 16868253 |
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Gilkes, AF,
Mills, KI,
Austin, SJ,
Burnett, AK,
Knapper, S,
Walsh, V
|
Blood |
2006 |
| 18068628 |
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Griffin, JD,
Golub, TR,
Gilliland, DG,
Heinrich, MC,
Ebert, BL,
Stone, RM,
Jiang, J,
Schittenhelm, MM,
Berger, R,
Lee, BH,
Deininger, MW,
Teckie, S,
Döhner, K,
Loriaux, M,
Fröhling, S,
Bernard, OA,
Scholl, C,
Boggon, TJ,
Levine, RL,
Döhner, H,
Druker, BJ
|
Cancer Cell |
2007 |
| 17827387 |
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin
Barry, EV,
Gilliland, DG,
Clark, JJ,
Cools, J,
Roesel, J
|
Blood |
2007 |
| 23392356 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
Yu, C,
Albers, C,
Verbeek, M,
Duyster, J,
Leischner, H,
Illert, AL,
von Bubnoff, N,
Peschel, C
|
Leukemia |
2013 |
| 27132990 |
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation
Huang, A,
Liu, K,
Wen, S,
Huang, P,
Liu, D,
Hu, Y,
Garcia-Manero, G,
Ju, HQ,
Zhan, G
|
Cancer Lett. |
2016 |
| 22858906 |
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
Nguyen, B,
Brown, P,
Li, L,
Levis, M,
Williams, AB,
Leahy, D,
Small, D
|
Leukemia |
2013 |
| 23969938 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
Mullighan, CG,
Baker, SD,
Rubnitz, JE,
Zimmerman, EI,
Orwick, S,
Inaba, H,
Neale, GA,
Zatechka, DS,
Buaboonnam, J,
Enemark, EJ,
Shurtleff, S,
Wang, YD,
Olsen, SR
|
Clin. Cancer Res. |
2013 |
